However, although intriguing, this was a secondary outcome that was not adjusted for multiplicity, and it was not accompanied by a clear reduction in CV death or major adverse CV events, so a direct CV explanation is uncertain and its possible non-CV drivers influenced the outcome, or even chance
By addressing these root causes, we dont just help you lose weight
Still, such treatment options can help improve a patients independence and overall quality of life by enhancing cardiovascular health, strength, range of motion, and pain relief
Aber auch bei einer Zulassung zur Gewichtsreduktion, ist diese bei den GLP-1-Rezeptoragonisten nicht von Dauer
Common examples include semaglutide, liraglutide, dulaglutide, and tirzepatide
An intuitive technology platform is a valuable tool in these follow-up visits